Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001347361 | SCV001541619 | uncertain significance | Intellectual disability, X-linked 1 | 2022-02-05 | criteria provided, single submitter | clinical testing | Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt IQSEC2 protein function. ClinVar contains an entry for this variant (Variation ID: 1043276). This missense change has been observed in individual(s) with X-linked intellectual disability (PMID: 30206421). This variant is not present in population databases (gnomAD no frequency). This sequence change replaces arginine, which is basic and polar, with tryptophan, which is neutral and slightly polar, at codon 1155 of the IQSEC2 protein (p.Arg1155Trp). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Genetics Laboratory, |
RCV001420264 | SCV001622684 | likely pathogenic | See cases | 2021-04-26 | criteria provided, single submitter | clinical testing | PM2_supporting;PM6_moderate;PP2_supporting;PP3_supporting |
Gene |
RCV001571476 | SCV001795960 | uncertain significance | not provided | 2023-10-20 | criteria provided, single submitter | clinical testing | Observed in the hemizygous state in two affected males from one family with intellectual disability (PMID: 30206421); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 36902414, 30206421) |